Neoadjuvant chemotherapy in ovarian cancer

Patients with advanced ovarian cancer have a chance of less than 50% after radical debulking surgery. In spite of the currently more effective combination chemotherapy agents that have become available as adjuvant therapy in the last decade, the prognosis of patients with residual tumor mass larger than 1 cm in diameter following surgery is still poor. Neoadjuvant or primary chemotherapy has been suggested as an alternative approach to primary laparotomy of the bulky ovarian cancer. The advantages and available data on neoadjuvant chemotherapy are discussed in this review.

Neodjuvant chemotherapy; Ovarian cancer

[1] FIGO.: "Annual report on the results of treatment in gynecological cancer". J. Epidem. Biostat., 1998, 3, 75.

[2] Landis S. H., Murray T., Bolden S.,W ingo P. A.: "Cancer statisties". CA Cancer J. Clin., 1999, 49, 8.

[3] Piccart M. J., Bertelsen K., James K. et al.: "Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: threeyear results". J. Natl. Cancer Inst., 2000, 92, 699.

[4] Hacker N. F., Berek J. S., Lagasse L. D., Neiberg R. K., Elashoff R. M.: "Primary cytoreductive surgery for epithelial over cancer". Obstet. Gynecol., 1983, 61,413.

[5] Hoskins W. J., Bundy B. N., Thigpen J. T., Omura G. A.: "The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study". Gynecol. Oneal., 1992, 47, 159.

[6] Bristow R. E., Tomacruz R. S., Armstrong D. K., Trimble E. L., Montz F. J.: "Survival impact of maximum cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: a metaanalysis of 6848 patients". Proc. ASCO 38'", San Francisco 2001, abs tr. no. 807.

[7] Chan K. K.: "Does the surgeon matter in the management of ovarian cancer?". Br. J. Cancer, 1999, 80, 1492.

[8] Gadducci A., Sartori E., Maggino T. et al.: "Analysis of failures after negative second- look in patients with advanced ovarian cancer: an Italian multicenter study". Gynecol. Oneal., 1998, 68, 150.

[9] Ozols F.: "Recent advances in ovarian cancer treatment". ASCO Educational Book, 1999, 25.

[10] Cannistra S. A.: Cancer of the ovary". N. Eng. J. Med., 1993, 329, 1550.

[11] Potter M. E., Partridge E. E., Hatch K. D. et al.: "Primary surgical therapy of ovarian cancer: how much and when". Gynecol. Oncol., 1991, 40, 195.

[12] Wils J., Blijharn G., Naus A. et al.: "Primary or delayed debulking surgery and chemotherapy consist of cispliatin, doxorubicin and cyclophospharnide in stage III-IV epithelial ovarian carcinoma". J. Clin. Oncol., 1986. 4, 1068.

[13] Neijt J. P., ten Bokkel Huinink W.W., van der Burg M. E. et al.: "Long term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for Ovarian Cancer". Eur. J. Cancer, 1991, 27, 1367.

[14] Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E. L. et al.: "Randomised trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovary carcinoma". J. Clin. Oncol., 1987, 5, 1157.

[15] Redman C. W., Warwick J., Luesley D. M., Varma R., Lawton F. G., Blackledge G. R.: "Intervention debulking surgery in advanced epithelial ovarian cancer". Br. J. Obst. Gynecol., 1994, 101, 142.

[16] van der Burg M. E., van Lent M., Buyse M. et al.: "The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer". N. Engl. J. Med., 1995, 332, 629.

[17] Lawton F. G., Redman C. W., Luesley D. M., Chan K. K., Blackledge G.: "Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer". Obstet. Gynecol., 1989, 73, 61.

[18] Ng L. W., Rubin S. C., Hoskins W. J. et al.: "Aggressive chemosurgical debulking in patient with advanced ovarian cancer". Gynecol. Oneal., 1990, 38, 358.

[19] Jacob J. H., Gershenson D. M., Morris M., Copeland L. J., Burke T. W., W harton T.: "Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer". Gynecol. Oneal., 1991, 42, 146.

[20] Lim J. T. W., Green J. A.: "Neoadjuvant carboplatin and ifosfomide for inoperabl FIGO stage III and IV ovarian carcinoma". Clin. Onco. (R. Coll. Radio/.), 1993, 5, 198.

[21] Surwit E. A., Childers J.M., Atlas I. I. et al.: "Neoadjuvant chemotherapy for advanced ovarian cancer". Int. J. Gynecol. Cancer, 1996, 6, 356.

[22] Schwartz P. E., Rutherford T. J., Chambers J. T., Kohorn E. I., Thiel R. P.: "Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival". Gynecol. Oncol., 1999, 72, 93.

[23] Houber J., Baster! G.,M eyer A., Schmid H., Grischke E.M ., Wall wiener D.: "Primary dose-intensified chemotherapy with cisplatin and treosulfan in advanced ovarian cancer". J. Cancer Res. Clin. Oncol., 2000, 126, abstr. no. 80.

[24] Kayikcioglu F., Kose M. F., Boran N., Calikan E., Tulunay G.: "Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma". Int. J. Gynecol. Cancer, 2001, 11, 466.

[25] Baranzelli M. C., Bouffet E., Quintana E., Portas M., Thyss A., Patte C.: "Non-seminomatous ovarian germ cell tumors in children". Eur. J. Cancer, 2000, 36, 376.

[26] Tempany C. M., Zou K. H., Silvermen S. G., Brown D. L., Kurtz A. B., McNeil B. J.: "Staging of advanced ovarian cancer: comparison of imagigng modalities-report from the Radiological Diagnostic Oncology Group". Radiology, 2000, 215, 767.

[27] Vergote I. B., de Wever I., Decloedt J., Tjalma W., Van Gramberen M., van Dam P.: "Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer". Semin. Oncol., 2000, 27 (3 Suppl 7), 31.